Targeting the latest hallmark of cancer: another attempt at ‘magic bullet’ drugs targeting cancers’ metabolic phenotype
| Autor: | Adrian S. Culf, Mohamed Touaibia, Natalie Lefort, Miroslava Cuperlovic-Culf |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Cancer Research
Chemical biology Bioinformatics Malignant transformation Metabolomics Neoplasms Humans Medicine Molecular Targeted Therapy Enzyme Inhibitors business.industry Drug discovery Lipogenesis Fatty Acids Antibodies Monoclonal Cancer General Medicine medicine.disease Small molecule Mitochondria Oncology Cancer cell business Magic bullet Glycolysis Metabolic Networks and Pathways |
| Zdroj: | Future Oncology. 8:1315-1330 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon.12.121 |
| Popis: | The metabolism of tumors is remarkably different from the metabolism of corresponding normal cells and tissues. Metabolic alterations are initiated by oncogenes and are required for malignant transformation, allowing cancer cells to resist some cell death signals while producing energy and fulfilling their biosynthetic needs with limiting resources. The distinct metabolic phenotype of cancers provides an interesting avenue for treatment, potentially with minimal side effects. As many cancers show similar metabolic characteristics, drugs targeting the cancer metabolic phenotype are, perhaps optimistically, expected to be ‘magic bullet’ treatments. Over the last few years there have been a number of potential drugs developed to specifically target cancer metabolism. Several of these drugs are currently in clinical and preclinical trials. This review outlines examples of drugs developed for different targets of significance to cancer metabolism, with a focus on small molecule leads, chemical biology and clinical results for these drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|